Mao inhibitors and Parkinson’s disease
Research profile of Moussa Youdim
Professor Moussa Youdim
Eve Topf and National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Teaching is an independent extension of the Department of Pharmacology at Technion-Rappaport Faculty of Medicine and has a close interaction with Rappaport Family Research Institute. It is dedicated to advancing the understanding of neuropsychiatric disorders, especially, neurodegenerative diseases.
The center’s main focus is to elucidate why and how neurons degenerate, employing cellular and animal models, and to develop novel drugs to prevent or rescue them. This is accomplished by implementation of conventional and novel biochemical techniques combined with chemistry, molecular biology, genomics and proteomics.
This has led to identification and development of several novel neuroprotective anti-Parkinson and anti-Alzheimer drugs including rasagiline, TV3326 and (-)-epigallocatechin-3-gallate (EGCG). The Centers have close relationships and collaborations with Teva Pharmaceutical Co. (Israel) and a number of major institutes in Israel and abroad. In collaboration with other organizations, Eve Topf Center has developed novel brain permeable neuroprotective iron chelators-MAO inhibitors for the treatment of neurodegenerative and systemic diseases, where misregulation of iron metabolism is implicated.
MAO inhibitors are still used in treating Parkinson’s Disease.